[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"type-1-diabetes-mellitus-t1dm\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:type-1-diabetes-mellitus-t1dm":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,49,84,122,143,181,232,270,303],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100625784","pediatric-insulin-plan-calculator-for-t1dm-management-100625784",false,"NCT07427134","Pediatric Insulin Plan Calculator for T1DM Management","Prospective, Parallel-Group Randomised Controlled Trial Evaluating a Flexible Insulin Dose Calculator in Paediatric Type 1 Diabetes Management","FLEXI-T1D","Inclusion Criteria:\n\n* Children and adolescents \\\u003C 12 years\n* Diagnosed with Type 1 Diabetes Mellitus (T1DM)\n* Duration of diagnosis \\> 1 year\n* Using a multiple daily injection (MDI) regimen\n* Practising carbohydrate counting for at least 1 month before enrolment\n\nExclusion Criteria:\n\n* Use of an existing insulin dose calculator (e.g., mobile application or bolus advisor) within the last 3 months\n* Diagnosis of other types of diabetes (e.g., Type 2 diabetes mellitus, monogenic diabetes)\n* Use of insulin regimens other than multiple daily injections (MDI) (e.g., insulin pump therapy)","ALL","1 Year","12 Years",{"count":21,"type":22},440,"ESTIMATED","INTERVENTIONAL",[25],"NA","This is a multi-centre, prospective, randomized, open-label controlled trial designed to evaluate the effectiveness of a flexible digital insulin dose calculator in children under 12 years of age with Type 1 Diabetes Mellitus (T1DM) managed with multiple daily injections (MDI). Participants will be stratified by continuous glucose monitoring (CGM) use and baseline HbA1c, and randomised to receive either standard care alone or standard care plus the insulin dose calculator tool for 6 months.\n\nThe primary outcome is the change in HbA1c from baseline to 6 months. Secondary outcomes include CGM-derived glycaemic metrics (Time in Range, Time Below Range, Time Above Range, and Coefficient of Variation), total daily insulin dose (units\u002Fkg\u002Fday), healthcare provider contact frequency, and caregiver-reported usability and satisfaction. The study aims to determine whether the use of a structured digital decision-support tool improves glycaemic control and supports safer insulin dosing in paediatric patients with T1DM.",[28,29,30,31],"Type 1 Diabetes Mellitus","Type 1 Diabetes Mellitus (T1DM)","T1DM","T1DM - Type 1 Diabetes Mellitus",[28,33,34,35],"Clinical Decision Support Tool","Digital Health Intervention","Insulin Dose Calculator","RECRUITING","2026-06-06",{"date":39,"type":40},"2026-06-09","ACTUAL",{"date":42,"type":40},"2026-05-03",{"date":44,"type":22},"2026-12-31",{"name":46,"class":47},"Sultan Qaboos University","OTHER",2,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":23,"phases":61,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":83},"100637548","phase-1-sequential-immune-modulation-and-antigen-specific-tolerance-induction-for-disease-modification-in-recent-onset-type-1-diabetes-100637548","NCT07610213","Sequential Immune Modulation and Antigen-Specific Tolerance Induction for Disease Modification in Recent-Onset Type 1 Diabetes","MATIN-2: Sequential Immune Modulation and Antigen-Specific Tolerance Induction for Disease Modification in Recent-Onset Type 1 Diabetes - A Mechanistic Framework and Phase I\u002FII Protocol Proposal","MATIN-2","Inclusion Criteria:\n\n* Age 18-45 years\n* Clinical diagnosis of Type 1 diabetes mellitus within 6 months of enrolment\n* Positive for at least one diabetes-related autoantibody (GAD65, IA-2, ZnT8, or IAA)\n* Detectable fasting or stimulated C-peptide ≥ 0.2 nmol\u002FL\n* HbA1c ≤ 10% (86 mmol\u002Fmol)\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* Prior immunosuppressive therapy within 3 months\n* Active or chronic infection (HIV, hepatitis B\u002FC, tuberculosis)\n* Current or prior malignancy within 5 years (except non-melanoma skin cancer)\n* Pregnancy or breastfeeding\n* Severe renal impairment (eGFR \\\u003C 30 mL\u002Fmin\u002F1.73m²)\n* Severe hepatic impairment (Child-Pugh C)\n* Known hypersensitivity to teplizumab or any excipient\n* Participation in another interventional trial within 30 days\n* Current systemic corticosteroid or immunomodulatory agent use\n* History of other autoimmune disease requiring immunosuppression\n* Absolute lymphocyte count \\\u003C 1.0 × 10⁹\u002FL\n* ALT or AST \\> 3× upper limit of normal\n* Haemoglobin \\\u003C 100 g\u002FL\n* Unwillingness to use contraception during study period","18 Years","45 Years",{"count":60,"type":22},60,[62],"PHASE1","This study tests a three-phase immune treatment for people recently diagnosed with Type 1 diabetes (within 6 months, with some insulin production remaining).\n\nPhase 1 (weeks 1-2): Teplizumab, an anti-CD3 antibody, is given by infusion to slow immune attack on insulin-producing beta cells.\n\nPhase 2 (months 2-9): Insulin is injected directly into a lymph node (intralymphatic immunotherapy, ILIT) alongside low-dose interleukin-2 to teach the immune system to tolerate insulin and expand protective regulatory T cells.\n\nPhase 3 (months 10-24): Low-dose interleukin-2 is continued to maintain immune tolerance.\n\nThe main goal is to preserve the body's remaining insulin production (measured by C-peptide). Sixty adults aged 18-45 will be randomly assigned to the MATIN-2 protocol or standard care. Safety, immune markers, and HbA1c will also be monitored.",[29,28,65],"Autoimmune Diabetes",[67,68,69,70,71,72],"teplizumab","intralymphatic immunotherapy","regulatory T cells","immune tolerance","C-peptide","beta cell preservation","NOT_YET_RECRUITING","2026-05-20",{"date":76,"type":40},"2026-05-27",{"date":78,"type":22},"2027-01-01",{"date":80,"type":22},"2030-06-01",{"name":82,"class":47},"Abdullah Kars",1,{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":92,"sex":17,"minAge":57,"maxAge":93,"enrollmentInfo":94,"targetDuration":4,"studyType":23,"phases":96,"briefSummary":97,"conditions":98,"keywords":102,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":83},"100610361","using-a-personalized-decision-support-tool-to-help-people-with-type-1-diabetes-manage-exercise-100610361","NCT07226583","Using a Personalized Decision Support Tool to Help People With Type 1 Diabetes Manage Exercise","Net-IOB & Exercise Toolkit Pilot Trial: Randomized, Crossover Evaluation of a Behavioral Decision Support Advisor to Improve Glycemic Safety During and After Exercise in Adults With Type 1 Diabetes (NEXT)","NEXT","Inclusion Criteria Inclusion Criteria: All Participants (Type 1 Diabetes and Healthy Control Groups)\n\n* Adults between the age of 18-60 years\n* Able to perform moderate intensity walking for 60 minutes (target 40-60% age-predicted maximal heart rate).\n* Willing and able to comply with study procedures, including supervised exercise visits and device wear\n* Able to provide written informed consent\n\nInclusion Criteria: Type 1 Diabetes Group Only\n\n* Clinical diagnosis of type 1 diabetes for \\>1 year, based on the investigator's clinical judgement\n* Current use of continuous subcutaneous insulin infusion with Tandem Control-IQ and a compatible continuous glucose monitor (CGM) for \\>1 month prior to enrollment\n* Stable insulin delivery regimen, with no planned changes to insulin pump settings or insulin dosing strategy during the study period\n* Consistent CGM use during the month prior to enrollment (\\>80% data availability)\n\nInclusion Criteria: Health Control Group Only\n\n* No diagnosis of diabetes or other disorders of glucose metabolism\n* Not using insulin or glucose-lowering medications\n\nExclusion Criteria Exclusion Criteria: All Participants\n\n* Intercurrent illness or medical condition that precludes safe participation in moderate-intensity exercise (e.g., unstable cardiopulmonary disease, uncontrolled arrhythmia, or uncontrolled hypertension), as previously assessed by the participant's primary care physician\n* Known coronary artery disease with symptoms limiting moderate physical activity, or history of myocardial infarction, percutaneous coronary intervention, or coronary artery bypass grafting within the past 12 months\n* Pregnancy, lactation, or plans to become pregnant during the study period\n* Renal insufficiency with estimated GFR \\\u003C45 mL\u002Fmin\u002F1.73 m², dialysis dependence, or adrenal insufficiency\n* Concurrent participation in another interventional drug or device study within 30 days prior to enrollment\n* Inability to comply with study procedures or safety requirements (e.g., inability to achieve target heart-rate zone, attend scheduled visits, or enable required device data access), or otherwise deemed unsuitable by the investigator\n\nExclusion Criteria: Type 1 Diabetes Group Only\n\n* Use of non-CSII insulin delivery, including long-acting injectable or inhaled insulin, during the study period\n* Use of medications with potential to substantially affect glycemia (e.g., SGLT-2 inhibitors, GLP-1 receptor agonists, or GIP agonists), unless on a stable regimen with no planned changes during the study\n* Use of systemic corticosteroids within 4 weeks prior to participation\n* History of severe hypoglycemia (requiring third-party assistance) or diabetic ketoacidosis within the prior 6 months",true,"60 Years",{"count":95,"type":22},20,[25],"This study evaluates a clinician-facing decision-support toolkit designed to assist adults with type 1 diabetes in preparing for moderate-intensity exercise. The netIOB \\& Exercise Toolkit (NEXT) integrates recent glucose data and insulin delivery history to provide individualized suggestions regarding exercise timing, insulin adjustments, and carbohydrate intake.\n\nAdults with type 1 diabetes will complete three supervised exercise sessions under different pre-exercise guidance approaches:\n\n(A) published consensus-based standard-of-care guidance, (B) usual personal care routines, and (C) guidance informed by the NEXT Toolkit.\n\nA healthy adult control group will complete a single supervised exercise session to provide comparative physiologic data.",[99,100,29,101],"Type 1 Diabetes Mellitis","Type 1 Diabetes (T1D)","Exercise Physiology",[103,104,30,105,106,107,108,109,110,111,112],"Type 1 Diabetes","T1D","Continuous Glucose Monitoring","Insulin Dosing","CGM","Insulin Pump","Exercise","carbohydrate Intake","closed-loop system","hybrid closed-loop","2026-05-11",{"date":115,"type":40},"2026-05-14",{"date":117,"type":22},"2026-04",{"date":119,"type":22},"2026-08",{"name":121,"class":47},"Stanford University",{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":126,"acronym":4,"eligibilityCriteria":127,"healthyVolunteers":11,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":128,"targetDuration":4,"studyType":23,"phases":129,"briefSummary":130,"conditions":131,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":83},"100581641","continuous-glucose-monitoring-for-outpatient-diabetes-management-after-hospital-discharge-100581641","NCT06852950","Continuous Glucose Monitoring for Outpatient Diabetes Management After Hospital Discharge","Inclusion Criteria:\n\n* Non-pregnant adults, ages greater than or equal to 18 years, admitted to VUMC\n* Able to give informed consent\n* Hyperglycemia requiring insulin therapy including subcutaneous insulin injection or continuous subcutaneous insulin infusion (patient's own insulin pump) during hospitalization and at the time of discharge\n* POC glucose or venous glucose levels in the 24 hours prior to participation need to be 70-350 mg\u002FdL\n* Need glucose readings greater than or equal to one time per day\n* Mental status and dexterity adequate to use Libre 3 Plus or Dexcom G7 sensors with Libre 3 or Dexcom G7 application on patient's smartphone\n\nExclusion Criteria:\n\n* Currently using Libre 3 Plus or Dexcom G7 CGMS during hospitalization or have used Libre 3 Plus or Dexcom G7 CGMS in the past 3 months\n* Does not have smartphone compatible with Libre 3 App or Dexcom G7 App\n* Received chemotherapy during current hospitalization\n* Planning on major surgery within 10-15 days\n* Hemodialysis or peritoneal dialysis\n* Requiring vasopressors, intubation, sedation, or admission to an intensive care unit\n* Vitamin C use of more than 500 milligrams per day\n* Hydroxyurea use\n* Acetaminophen use of more than 4 grams per day or 1 gram every 6 hours\n* Significant pitting edema (3+ or greater) i.e. cirrhosis with ascites, congestive heart failure with edema, nephrotic syndrome, or signs of poor perfusion\n* Presentation in diabetic ketoacidosis or hyperosmotic nonketotic state\n* Skin allergy to adhesives",{"count":60,"type":22},[25],"This study aims to improve patient awareness of the utility of continuous glucose monitoring systems in blood glucose monitoring and to improve patient satisfaction regarding diabetes care, particularly in the matter of blood glucose monitoring, at the transitions of care from the inpatient setting to the ambulatory setting.",[132,29,133],"Type 2 Diabetes Mellitus (T2DM)","Hyperglycemia","2026-03-02",{"date":136,"type":40},"2026-03-05",{"date":138,"type":40},"2025-03-09",{"date":140,"type":22},"2027-01",{"name":142,"class":47},"Vanderbilt University Medical Center",{"id":144,"slug":145,"hasResults":11,"nctId":146,"briefTitle":147,"officialTitle":148,"acronym":149,"eligibilityCriteria":150,"healthyVolunteers":11,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":151,"targetDuration":4,"studyType":23,"phases":153,"briefSummary":154,"conditions":155,"keywords":160,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":83},"100607937","thai-painpredict-validation-study-100607937","NCT07195045","Thai PainPREDICT Validation Study","Thai Version of PainPREDICT: Translation, Validation, and Mobile Application Development for Screening Painful Diabetic Neuropathy in Diabetes Patients","PainPREDICT-Th","Inclusion Criteria:\n\n* Adults aged 18 years or older.\n* Diagnosed with type 1 diabetes mellitus or type 2 diabetes mellitus.\n* Able to communicate in Thai.\n* Willing and able to provide written informed consent.\n\nExclusion Criteria:\n\n* Presence of neuropathy due to other causes (e.g., alcohol, chemotherapy, HIV, other systemic diseases).\n* Significant cognitive impairment or neurological conditions that prevent comprehension of the questionnaire.\n* Severe psychiatric illness that interferes with study participation.",{"count":152,"type":22},277,[25],"Painful diabetic neuropathy (PDN) is one of the most common and disabling complications of diabetes mellitus, substantially affecting quality of life, daily functioning, and health system burden. Early identification of PDN is crucial for timely treatment, prevention of complications such as foot ulcers and amputations, and for reducing healthcare costs. However, in Thailand there are limited culturally adapted and validated tools for screening PDN. PainPREDICT is an internationally validated questionnaire designed to characterize neuropathic pain profiles, but its adaptation for Thai patients has not yet been undertaken. In parallel, the use of mobile health technologies (mHealth) has the potential to expand access to screening and monitoring of chronic conditions, particularly in resource-limited settings.",[156,157,29,132,158,159],"Painful Diabetic Neuropathy (PDN)","Diabetic Neuropathy, Distal Symmetric Polyneuropathy (Manifestation)","Neuropathic Pain","Diabetes Complications",[161,162,163,164,165,166,167,168,169,170,159,171],"PainPREDICT","Painful Diabetic Neuropathy","Diabetic Neuropathy","Neuropathic Pain Questionnaire","Mobile Health (mHealth)","Questionnaire Validation","Screening Tool","Thai Population","Cross-Cultural Adaptation","Digital Health Application","Neuropathy Screening","2025-09-29",{"date":174,"type":40},"2025-10-03",{"date":176,"type":40},"2025-08-28",{"date":178,"type":22},"2027-12-31",{"name":180,"class":47},"Chulalongkorn University",{"id":182,"slug":183,"hasResults":11,"nctId":184,"briefTitle":185,"officialTitle":185,"acronym":186,"eligibilityCriteria":187,"healthyVolunteers":11,"sex":17,"minAge":188,"maxAge":189,"enrollmentInfo":190,"targetDuration":4,"studyType":192,"phases":4,"briefSummary":193,"conditions":194,"keywords":218,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":229,"locationsCount":231},"100599630","cardiovascular-risk-in-children-with-chronic-conditions-study-100599630","NCT07086989","Cardiovascular Risk in Children With Chronic Conditions Study","CR3C","Inclusion criteria:\n\n1. Individuals aged between 6 and 25 years;\n2. Diagnosed with a chronic childhood condition\u002Fdisease associated with an increased risk of early cardiovascular disease;\n3. Provided informed consent (if over 18 years old) or had informed consent provided by their legal guardian (if under 18 years old) following appropriate information about the study.\n\nChronic childhood conditions\u002Fdiseases associated with increased risk of early cardiovascular disease are defined according to the 2019 American Heart Association recommendations (https:\u002F\u002Fdoi.org\u002F10.1161\u002FCIR.0000000000000618), as well as other conditions\u002Fdiseases for which at least two large-scale epidemiological studies have demonstrated an increased risk of cardiovascular disease.\n\nExclusion criteria:\n\n1. Severe intellectual and developmental disability;\n2. Decompensated heart failure;\n3. Severe primary immunodeficiency;\n4. Ongoing intravenous chemotherapy;\n5. Infectious diseases posing a public health risk; or\n6. History of regular alcohol or drug use.","6 Years","25 Years",{"count":191,"type":22},300,"OBSERVATIONAL","Children living with chronic health conditions face a higher risk of developing cardiovascular diseases than their peers, largely due to the accelerated aging of the heart and blood vessels. Although experts recognize this elevated risk and recommend close monitoring and early intervention, the underlying mechanisms driving this phenomenon remain poorly understood. At present, no effective interventions specifically target its root causes.\n\nRecent research shows that both large blood vessels (such as the carotid artery) and small vessels (such as those in the retina) can display early signs of damage decades before clinically apparent heart or vascular disease emerges. This accelerated vascular aging can result from multiple factors - including disease-related processes such as persistent inflammation and metabolic disturbances, treatment-related effects such as chemotherapy or long-term steroid use, and lifestyle changes associated with chronic illness, such as reduced physical activity and altered eating habits. However, it is still unclear how these factors influence the development and progression of vascular changes in children as they grow. Importantly, these changes can be monitored through non-invasive methods, offering a unique opportunity to study at-risk patients many years before overt cardiovascular disease develops.\n\nIdentifying these early changes may enable us to detect and track individuals at heightened risk well in advance of clinical disease. This study aims to deepen our understanding of the causes of increased cardiovascular risk in children with chronic conditions and to lay the groundwork for earlier, more targeted prevention strategies.",[195,196,29,132,197,198,199,200,201,202,203,204,205,206,207,208,209,210,211,212,213,214,215,216,217],"Kidney Transplant","Familial Hypercholesterolaemia","Chronic Kidney Disease","Kawasaki Disease","Liver Transplant","Obesity and Overweight","Hypertension","Coarctation of Aorta","Bone Marrow Transplant","Cancer (Solid Tumors)","Leukemia","Lymphoma","Lipoprotein(a)","Aorta Stenosis","Non Alcoholic Fatty Liver Disease","Dyslipaemia","White Coat Hypertension","Pulmonary Hypertension","Juvenile Idiopahtic Arthritis","Systemic Lupus Erthematosus","Inflammatory Bowel Disease (IBD)","HIV Infection","Transposition of Great Arteries",[219,220,221],"cardiovascular risk","vasculature","children with chronic conditions","2025-08-04",{"date":224,"type":40},"2025-08-08",{"date":226,"type":40},"2025-04-01",{"date":228,"type":22},"2029-01-31",{"name":230,"class":47},"Semmelweis University",3,{"id":233,"slug":234,"hasResults":11,"nctId":235,"briefTitle":236,"officialTitle":237,"acronym":238,"eligibilityCriteria":239,"healthyVolunteers":11,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":240,"targetDuration":4,"studyType":23,"phases":242,"briefSummary":244,"conditions":245,"keywords":254,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":263,"startDateStruct":264,"completionDateStruct":266,"leadSponsor":268,"locationsCount":83},"100585948","phase-3-semaglutide-treatment-in-type-1-diabetes-100585948","NCT06909006","Semaglutide Treatment in Type 1 Diabetes","Obesity and Semaglutide in Type 1 Diabetes Therapy: A Multicentre, Randomised, Double-Blinded, Placebo-Controlled, Investigator-Initiated Trial","OBES1TY","Inclusion Criteria:\n\n* Type 1 Diabetes for more than 3 years\n* BMI ≥ 30 or ≥ 27 and atleast one comorbidity (hypertension, hypercholesterolemia, microalbuminuria, ischemic heart disease, history of stroke, atherosclerosis or arthrosis\n\nExclusion Criteria:\n\n* Treated with GLP1-RAs within last 6 months\n* Known intolerance for semaglutide\n* Other forms of diabetes\n* Pregnant or nursing women\n* Fertile women not using chemical (hormonal) or mechanical (spiral) contraceptives\n* Liver disease with elevated plasma alanine aminotransferase (ALT) \\> five times and plasma aspartate aminotransferase (AST) \\> five times the upper limit of normal (measured at visit 0 with the possibility of one repeat analysis within a week, and the last measured value as being conclusive)\n* Acute or chronic pancreatitis\n* Cancer, unless in complete remission for \\> 5 years or unless basocellular carcinomas\n* History of thyroid adenoma or carcinoma\n* Alcohol\u002Fdrug abuse\n* Other concomitant disease or treatment that according to the investigator's assessment makes the patient unsuitable for study participation\n* Receipt of an investigational drug within 30 days prior to visit 0 \u002F Simultaneous participation in any other clinical intervention trial",{"count":241,"type":22},122,[243],"PHASE3","The goal of this clinical trial is to investigate the efficacy of semaglutide on body weight, insulin dose requirements and improvements in glucose control and safety aspects in regards to risk of hypoglycemia and diabetic ketoacidosis for patients with established Type 1 Diabetes.",[246,247,29,248,249,250,251,252,253],"Obesity in Diabetes","Obesity\u002FTherapy","Insulin Sensitivity\u002FResistance","Semaglutide","Lipidomics","Metabolomics","Weight Loss","Glycemic Control for Diabetes Mellitus",[249,255,103,256,257,258,259,260,261,262],"Obesity","Obese Type 1 Diabetics","Insulin sensitivity","Insulin resistance","Weight loss","GLP1-RA","GLP1","Wegovy",{"date":224,"type":40},{"date":265,"type":22},"2025-10",{"date":267,"type":22},"2028-06",{"name":269,"class":47},"Nordsjaellands Hospital",{"id":271,"slug":272,"hasResults":11,"nctId":273,"briefTitle":274,"officialTitle":275,"acronym":4,"eligibilityCriteria":276,"healthyVolunteers":11,"sex":17,"minAge":277,"maxAge":278,"enrollmentInfo":279,"targetDuration":4,"studyType":23,"phases":281,"briefSummary":282,"conditions":283,"keywords":284,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":294,"lastUpdatePostDateStruct":295,"startDateStruct":297,"completionDateStruct":299,"leadSponsor":301,"locationsCount":83},"100591723","structured-education-program-and-glycemic-control-in-adolescents-with-type-1-diabetes-100591723","NCT06984133","Structured Education Program and Glycemic Control in Adolescents With Type 1 Diabetes","Evaluating the Effectiveness of a Structured Educational Program on Glycemic Control in Adolescents With Type 1 Diabetes: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Arab adolescents\n* Males and females aged 11 to 14 years.\n* Have been diagnosed with type 1 diabetes for at least 6 months.\n* Wearing a continuous glucose monitor (CGM).\n* Individuals and their parents must be able to join the entire duration of the study.\n* Individuals and their parents must voluntarily provide consent and assent.\n\nExclusion Criteria:\n\n* Presence of learning disabilities or any known psychological issues.\n* Attendance at any diabetes education or carbohydrate counting programs within the six months preceding the study.","11 Years","14 Years",{"count":280,"type":22},128,[25],"Type 1 diabetes is becoming more common in Kuwaiti and Arab adolescents. Many young people with this condition struggle to keep their blood glucose levels under control, which can lead to diabetes-related complications and affect their quality of life.\n\nThe goal of this clinical trial is to evaluate the effectiveness of a structured educational program on glycemic control among Arab adolescents with type 1 diabetes aged 11 to 14 years.\n\nParticipants will be randomly assigned to one of two groups. The intervention group will receive the structured education program, and the control group will continue with standard care.\n\nAll participants will undergo assessments that include:\n\n* collecting demographic and diabetes management data\n* measuring weight and height\n* measuring HbA1c levels and lipid profile\n* filling out questionnaires on quality of life, carbohydrate and insulin dosing knowledge, physical activity\n* collecting dietary intake\n* providing AGP report\n\nParticipants in the intervention group will additionally be required to:\n\n* attend the program for 4 consecutive days, one day for parents and three days for children\n* fill out 3-day food diary records during the program\n* attend a refresher course after 6 months\n\nParticipants in the control group will have the opportunity to participate in the program after approximately six months.",[100,29],[285,286,287,288,289,290,291,292,293],"Kuwait","Glycemic control","Type 1 diabetes","Carbohydrate counting","Arab adolescents","Structured education","Adolescents","Diabetes education program","HbA1c","2025-05-14",{"date":296,"type":40},"2025-05-22",{"date":298,"type":22},"2025-05-18",{"date":300,"type":22},"2028-05-18",{"name":302,"class":47},"Dasman Diabetes Institute",{"id":304,"slug":305,"hasResults":11,"nctId":306,"briefTitle":307,"officialTitle":308,"acronym":4,"eligibilityCriteria":309,"healthyVolunteers":11,"sex":17,"minAge":310,"maxAge":57,"enrollmentInfo":311,"targetDuration":4,"studyType":23,"phases":313,"briefSummary":314,"conditions":315,"keywords":318,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":325,"lastUpdatePostDateStruct":326,"startDateStruct":328,"completionDateStruct":330,"leadSponsor":332,"locationsCount":83},"100564921","motivational-interviewing-and-whatsapp-based-monitoring-for-metabolic-control-and-self-efficacy-in-adolescents-with-t1dm-100564921","NCT06635460","Motivational Interviewing and WhatsApp-Based Monitoring for Metabolic Control and Self-Efficacy in Adolescents With T1DM","The Impact of Motivational Interviewing and Social Media-Based Patient Monitoring on Metabolic Control and Self-Efficacy in Adolescents With Type 1 Diabetes: A Randomized Controlled Trial","Inclusion criteria:\n\n* 13-18 years old,\n* Diagnosed with type 1 DM at least 6 months ago,\n* HbA1C level \\>7.0,\n* 3-monthly outpatient visits,\n* Completed basic type 1 DM education and scored high (≥15 points) on the Type 1 Diabetes Knowledge Assessment Form,\n* A WhatsApp user with a smart phone and internet access,\n* Adolescents who can speak and understand Turkish.\n\nExclusion criteria:\n\n* Using an insulin pump,\n* Having a chronic disease other than diabetes,\n* Cognitive, intellectual, hearing, vision, or speech disabilities","13 Years",{"count":312,"type":22},56,[25],"This clinical study aims to determine the effects of motivational interviewing and social media-based patient monitoring on metabolic control and self-efficacy in adolescents with Type 1 diabetes. Additionally, the study will assess the adolescents\\' attitudes toward their disease, quality of life, and perceived levels of social support. The primary research questions are as follows:\n\nFor adolescents with Type 1 diabetes who receive motivational interviewing and social media-based monitoring:\n\nHow do their attitudes toward their disease compare to those in the control group? How do their perceived levels of social support compare to those in the control group? How do their self-efficacy levels compare to those in the control group? How does their quality of life compare to that of the control group? How do their HbA1c levels compare to those in the control group?",[29,316,317],"Motivational Interviewing","Metabolic Control",[319,320,321,322,323,324],"Type 1 diabetes mellitus","adolescent","motivational interviewing","social media-based monitoring","metabolic control","Self efficacy","2024-10-08",{"date":327,"type":40},"2024-10-10",{"date":329,"type":22},"2024-10-15",{"date":331,"type":22},"2025-04-15",{"name":333,"class":47},"Istanbul Medeniyet University"]